Skip to main content
. 2021 Feb 1;42(5):1687–1695. doi: 10.1007/s10072-021-05049-w

Fig. 3.

Fig. 3

Two-dimensional graphs showing the values of SUCRA for efficacy and acceptability of the S1P receptor used in the treatment of multiple sclerosis. X-axis: EARR; Y-axis: serious adverse events leading to discontinuation of trials (A = Fingolimod (1.25 mg), B = Fingolimod (0.5 mg), C = Interferon, D = Placebo, E = Laquinimod (0.6 mg), F = Siponimod (2 mg), G = Ozanimod (1 mg), H = Ozanimod (0.5 mg), I = Amiselimod (0.4 mg), J = Amiselimod (0.4 mg), K = Amiselimod (0.1 mg), L = Ponesimod (10 mg), M = Ponesimod (20 mg), N = Ponesimod (40 mg))